Table 3.

Adverse events of the two groups of patients

	HDDT (n = 110)	HT (n = 117)	P-value
Overall adverse events, n (%)	8 (7.3%)	17 (14.5%)	0.081
Abdominal pain, n (%)	3 (2.7%)	2 (1.7%)	0.602
Constipation, n (%)	2 (1.8%)	0 (0)	0.143
Diarrhea, n (%)	1 (0.9%)	9 (7.7%)	0.013
Dizziness, n (%)	1 (0.9%)	3 (2.6%)	0.344
Headache, n (%)	1 (0.9%)	0 (0)	0.301
Nausea/vomiting, n (%)	2 (1.8%)	9 (7.7%)	0.039
Skin rash, n (%)	0 (0)	0 (0)	–
Bad taste, n (%)	0 (0)	0 (0)	–

HDDT: high-dose dual therapy (rabeprazole 20 mg and amoxicillin 750 mg q.i.d for 14 days); HT: hybrid therapy (rabeprazole 20 mg and amoxicillin 1 g b.i.d. for 7 days, followed by rabeprazole 20 mg, amoxicillin 1 g, clarithromycin 500 mg and metronidazole 500 mg b.i.d. for 7 days); SD: standard deviation